Top Articles - Finance

Are you looking to outperform the market and optimize your profits but are not sure how to pick the right stocks? Has investing become a chore? Do you find yourself investing in hot stock

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

s after they have made their big move? Would you like to learn how I increased my portfolio by over 400% in under 7 years? Do you want to discover how I have outperformed the market over th

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

e past 3 years by a margin of 5 to 1?

Do You Hate Research? . . . I do!

I have always wanted to find an investment strategy that made sense. An investment strategy in which I do not need

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

to know the intricacies of the market, predict market trends or follow specific stocks. How can I get the inside information of what is hot before the rest of the market knows? I can't. N

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

or do I need to.

Plus, I don't have that kind of time to commit to in-depth research. Like you, I have a regular job that I need to devote my time to. I am not a day trader; nor do I wan

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

to spend all of my free time on the computer doing research. Always following the stock market and getting stock quotes is not how I want to spend my free time.

I Avoid Individual Stocks

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

. . . they are too unreliable!

Everybody wants to buy low and sell high. While millions of people do make money this way (and many millions loose money), I have found an easier and more e

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

fective way to use the market to my advantage. I do not trade in stocks. I do what I can to avoid individual stocks. And I consistently beat the market . . . month after month after month

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

.

If not stocks, what's the alternative?

Like many people, I got heavily involved in the stock market in the mid to late Nineties. Tech stocks were going through the roof and I, like eve

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

ybody else, wanted a part of the action. It seemed an easy way to make money. Everybody was getting rich. You did not need a special investment strategy to beat the market.

During this

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

time, I engrossed myself in the financial markets. I wanted to learn as much as I could without giving up my day job. I was trying to find the next best tech stock, IPOs and the occasiona

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

l pre-IPO offering. But it was not until I discovered options trading that I discovered an investment strategy (The Yager Trading Strategy) that can work in any kind of market . . . Bull,

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

ear or stagnant.

That's right...OPTION trading!

And I am not talking about stock options or writing covered calls. Options trading...I started selling options on S&P futures, using differ

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

ent methods and trading strategies. And I did well. VERY well.

Between July 1998 and January 2000 (a span of 18 months), from my option trading system, I turned an initial $25,000 investm

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

nt into $167,615. That's over 670% increase. And this was not paper money where you buy a stock and it has a certain listed value. This was real, taxed income. Profits collected on a mo

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

nthly basis.

Market fluctuations and volatility have diminished greatly since then...reducing the premiums. Those types of returns are no longer available, but the option trading strategy

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

is still very sound. I still consistently beat the market. Even the years the DJIA, Nasdaq and S&P were all down, I posted more than a 22% gain.

Learn the option trading strategy or see

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

how to make money with this strategy. I describe the strategy and show actual recent trades on www.yagerinvesting.com. The information is FREE. No subscription required. This is a method

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

for risk capital only.

For the preceding 12 months (May '06 through April '07) this is how my strategy, The Yager Trading Strategy, performed:

DJIA..............…..…….......15.0%

NASDAQ.

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

................……....8.7%

S & P 500...........…..….....13.2%

Yager Trading Strategy...26.3%

Learn the strategy for FREE.
http://www.yagerinvesting.com
adam@yagerinvesting.co

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.toparticles.org.ua/article/116471/toparticles-A-Trading-Strategy-The-Consistently-Beats-All-Major-Indexes.html">A Trading Strategy The Consistently Beats All Major Indexes</a>

BB link (for phorums):
[url=http://www.toparticles.org.ua/article/116471/toparticles-A-Trading-Strategy-The-Consistently-Beats-All-Major-Indexes.html]A Trading Strategy The Consistently Beats All Major Indexes[/url]

So your life is taking a different direction...it's time to change careers. Where do you start? Read 6 valuable, easy tips to help you launch the search now.

Looking from this angle, it would seem backlinks and PageRank complement one another. In other words, the more the backlinks a webpage has, greater will be its PageRank. Available evidence however does not always support this.

You may have a strong desire and stronger need to purchase a car but improper funds may create hindrance. Car loans can help you overtake the hindrance and get a car of your own.

Tags

Links

Top Articles - A Trading Strategy The Consistently Beats All Major Indexes

Related Articles: